

Curriculum Vitae

Personal information **Dina Schadel**

Work experience

April 2023 - present Paul-Ehrlich-Institute, Langen, Germany, Section Clinical Evaluation Immunology (IMG1)

Clinical Assessor with a focus on oncology

- Clinical assessment of clinical trial applications and substantial modification applications
- EMA scientific advice, national scientific advice

May 2017 - April 2023 Heidelberg Pharma Rersearch GmbH, Ladenburg, Germany

Study Director Preclinical Studies

- Coordination, supervision & oversight of in-vivo studies including communications with the monitor, responding to queries and interpretation of data
- Attending project team meetings including presenting results and planning of next studies and contribution to study strategy
- Examination of study animals and interpretation of drug-related toxicology findings (gross- and histopathology, blood chemistry and hematology)

May 2013 - April 2017 Paul-Ehrlich-Institute, Langen, Germany

PhD student in the research group of Prof. Dr. C. J. Buchholz (Molecular Biotechnology and Gene Therapy)

- Doctoral thesis: "Comparative studies of recombinant oncolytic viruses for the treatment of CD133-positive tumors", grade: Summa Cum Laude
- Preclinical evaluation of antitumoral activity and safety of different oncolytic viruses
- Minor projects and scientific involvement: a) Generation and preclinical evaluation of AAV and lentiviral vectors for genetic manipulation of endothelial cells; b) Histological evaluation of tissue sections from mice treated with CAR T cells to study acute toxicity
- Regular presentation of scientific results at national and international conferences (poster and talk)
- Attendance at internal workshops, seminars and journal clubs including workshops of drug regulation

August 2012 - February 2013 Institute for Veterinary Pharmacology and Toxicology, Justus Liebig University Giessen, Germany and TransMIT GmbH, Giessen, Germany

Research Assistant in the research group of Prof. Dr. J. Geyer

- Project: Interaction of anticholinergics with the drug transporter of the liver
- Molecular genetics diagnostics of the nt230(del4) MDR1 mutation in dogs (TransMIT GmbH)

May 2012 - July 2012 The Pirbright Institute, Pirbright, Great Britain

Visiting Research Assistant in the research group of Dr. D. Schley (Mathematical Modelling)

- Project: Within-group contact of cattle in dairy barns and the implications for disease transmissions
- Scholarship "Leonardo da Vinci" granted by the German Academic Exchange Service DAAD and the European Commission

October 2009 - October 2010 Small Animal Hospital, Justus Liebig University Giessen, Germany

Clinical Elective

February 2006 - October 2006 Crelux GmbH, Martinsried, Germany

- Biological Science Technician in the Laboratory for Molecular Biology

January 2005 - October 2005 Clinical diagnostic laboratory Dr. Eveld and Dr. Gyenes, Department Clinical Microbiology

Education and training

May 2013 - April 2017 Paul-Ehrlich-Institute, Langen, Germany

Disputation: 04-07-2019

Dr. med. vet, grade: Summa Cum Laude

Doctoral thesis: "Comparative studies of recombinant oncolytic viruses for the treatment of CD133-positive tumors"

October 2006 - April 2012 Justus Liebig University, Giessen, Germany

State Examination, grade: 2.5

Licence to practise Veterinary Medicine

August 2001 - September 2004 Lessing Gymnasium und Berufskolleg Düsseldorf, Germany

Abitur (German general qualification for university entrance) and Biological Science Technician

Additional information

Publications

CD30-Targeted Oncolytic Viruses As Novel Therapeutic Approach Against Classical Hodgkin Lymphoma

Hanauer JDS, Rengstl B, Kleinlützum D, Reul J, Pfeiffer A, Friedel T, Schneider IC, Newrzela S, Hansmann ML, Buchholz CJ Muik A
Oncotarget, 2018, 9 (16), 12971-12981

Enhancing the Oncolytic Activity of CD133-Targeted Measles Virus: Receptor Extension or Chimerism With Vesicular Stomatitis Virus Are Most Effective
Kleinlützum D, Hanauer JDS, Muik A, Hanschmann KM, Kays SK, Ayala-Breton C, Peng KW, Mühlebach M, Abel T and Buchholz CJ *Frontiers in Oncology*, 2017, 7, 127

Endothelial Transcription Factor KLF2 Negatively Regulates Liver Regeneration Via Induction Of Activin A

Manavski Y, Abel, T, Hu J, Kleinlützum D, Buchholz CJ; Belz C, Augustin HG; Boon RA, Dimmeler S
PNAS, 2017, 114 (15), 3993-3998

A Case Of Gallstones In An African Green Monkey (*Chlorocebus aethiops*)

Kleinlützum D, Plesker R
Primate Biology, 2017, 4, 33-37

Within-Group Contact Of Cattle In Dairy Barns And The Implications For Disease Transmission

Kleinlützum D, Weaver G, Schley D
Research in Veterinary Science, 2013, 95 (2), 425-429

Projects

Memberships

Oral presentation at scientific conferences:

Oncolytic Viruses Retargeted To The Tumor Stem Cell Marker CD133

Kleinlützum D, Muik A, Hanauer JDS, Kays SK, Ayala-Breton C, Peng KW,

Buchholz CJ

27. Annual Meeting of the Society for Virology (GfV), Marburg, 2017 Mar

Oncolytic Vesicular Stomatitis Virus Retargeted to The Tumor Stem Cell Marker CD133

Kleinlützum D, Muik A, Kays SK, Ayala-Breton C, Peng KW, Buchholz CJ

60. Jahrestagung und 22. Schnittseminar der Fachgruppe Pathologie der Deutschen Veterinärmedizinischen Gesellschaft, Fulda, 2017 Mar

Oncolytic Vesicular Stomatitis Virus Retargeted to The Tumor Stem Cell Marker CD133

Kleinlützum D, Muik A, Hanauer JDS, Kays SK, Ayala-Breton C, Peng KW, Buchholz CJ

Annual PEI Retreat, Ronneburg, 2017 Jan

Oncolytic Vesicular Stomatitis Virus Retargeted To The Tumor Stem Cell Marker CD133

Kleinlützum D, Muik A, Hanauer JDS, Kays SK, Ayala-Breton C, Peng KW, Buchholz CJ

22nd Annual Meeting of the German Society for Gene Therapy (DGGT), Heidelberg, 2016 Sept

Oncolytic Vesicular Stomatitis Virus Retargeted To Tumor Stem Cells

Kleinlützum D, Muik A, Kays SK, Bönig H, Buchholz CJ

Summer School of the LOEWE Cell and Gene Therapy (CGT), Langen, 2015 Oct

Poster presentation at scientific conferences:

Oncolytic Vesicular Stomatitis Virus Retargeted To The Tumor Stem Cell Marker CD133

Kleinlützum D, Muik A, Hanauer JDS, Kays SK, Ayala-Breton C, Peng KW, Buchholz CJ

American Society of Gene & Cell Therapy Meeting, Washington DC, 2016 Mar

Oncolytic Vesicular Stomatitis Virus Retargeted to The Tumor Stem Cell Marker CD133

Kleinlützum D, Muik A, Hanauer JDS, Kays SK, Ayala-Breton C, Peng KW, Buchholz CJ

7. UCT Science Day, Frankfurt a.M., 2016 Oct

Oncolytic Vesicular Stomatitis Virus Retargeted To The Tumor Stem Cell Marker CD133

Kleinlützum D, Muik A, Kays SK, Bönig H, Buchholz CJ
Annual PEI Retreat, Ronneburg, 2016 Jan

Transgene-Armed Measles Virotherapeutics Targeted Against Cancer Stem Cells

Kleinlützum D, Muik A, Kays SK, Buchholz CJ
Annual PEI Retreat, Heidelberg, 2015 Jan

Stem Cell Targeted And Transgene Armed Measles Virotherapeutics

Kleinlützum D, Muik A, Kays SK, Bönig H, Buchholz CJ
Summer School of the LOEWE Cell and Gene Therapy (CGT), Bad Nauheim, 2014 Oct

Cancer Stem Cell Targeted And Transgene-Armed Measles Virotherapeutics

Kleinlützum D, Muik A, Buchholz CJ
Annual PEI Retreat, Heidelberg, 2014 Jan

Other Relevant Information